Skip to main content

Abridge vs Nabla

Side-by-side on valuation, funding, investors, founders & more

Comparison updated: April 2026

Abridge is valued at $5.3B — more than 3x Nabla's $180M.

Head-to-Head Verdict

Abridge leads on 4 of 5 metrics

Abridge

4 wins

+Valuation
+Funding
+Awaira Score
+Team Size
=Experience

Nabla

0 wins

-Valuation
-Funding
-Awaira Score
-Team Size
=Experience

Key Numbers

Valuation
$5.3B
$180M
Total Funding
$800M
$131M
Awaira Score
76/100
73/100
Employees
120
80
Founded
2018
2018
Stage
Series E
Series C
AbridgeNabla
Winner
Abridge logo
Abridge

🇺🇸 United States · Shiv Rao

Series EAI HealthcareEst. 2018

Valuation

$5.3B

Total Funding

$800M

Awaira Score76/100

120 employees

Full Abridge Profile →
Nabla logo
Nabla

🇫🇷 France · Alexandre Lebrun

Series CAI HealthcareEst. 2018

Valuation

$180M

Total Funding

$131M

Awaira Score73/100

80 employees

Full Nabla Profile →
Market Context

As AI Healthcare players, Abridge and Nabla target overlapping customers despite operating from different countries. The stage gap — Abridge at Series E vs Nabla at Series C — shapes how each company allocates capital and talent.

🔬

Analyst Summary

Built from real data · Updated April 2026

Companies

The AI Healthcare sector features both Abridge and Nabla as key players. Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows.

Funding & Valuation

A 29.4x valuation gap separates these companies — Abridge at $5.3B and Nabla at $180M. With $800M raised, Abridge has attracted substantially more capital than Nabla ($131M).

Growth Stage

Both companies were founded in 2018, giving them equivalent market tenure. Stage-wise, Abridge is classified as Series E and Nabla as Series C, reflecting divergent fundraising histories. On headcount, Abridge reports 120 employees and Nabla reports 80.

Geography & Outlook

Based in 🇺🇸 United States and 🇫🇷 France respectively, Abridge and Nabla tap into different talent markets and regulatory environments. The Awaira Score reflects a tight race: 76 for Abridge versus 73 for Nabla. Abridge, led by Shiv Rao, and Nabla, led by Alexandre Lebrun, each bring distinct leadership visions to the AI sector.

Funding Velocity

Abridge

Total Rounds4
Avg. Round Size$69M
Funding Span4 yrs

Nabla

Total Rounds1
Avg. Round SizeN/A

Funding History

Abridge has completed 4 funding rounds, while Nabla has gone through 1. Abridge's most recent round was a Series C of $150M, compared to Nabla's Seed. Abridge is at Series E while Nabla is at Series C — different points in their growth trajectory.

Team & Scale

Team sizes are in the same ballpark: Abridge has about 120 people and Nabla has around 80. Both companies were founded in 2018. Geographically, they're in different markets — Abridge operates out of United States and Nabla from France.

Metrics Comparison

MetricAbridgeNabla
💰Valuation
$5.3BWINS
$180M
📈Total Funding
$800MWINS
$131M
📅Founded
2018
2018
🚀Stage
Series E
Series C
👥Employees
120
80
🌍Country
United States
France
🏷️Category
AI Healthcare
AI Healthcare
Awaira Score
76WINS
73

Key Differences

💰

Valuation gap: Abridge is valued 29.4x higher ($5.3B vs $180M)

📈

Funding gap: Abridge has raised $669M more ($800M vs $131M)

🚀

Growth stage: Abridge is at Series E vs Nabla at Series C

👥

Team size: Abridge has 120 employees vs Nabla's 80

🌍

Market base: 🇺🇸 Abridge (United States) vs 🇫🇷 Nabla (France)

⚔️

Direct competitors: Both operate in the AI Healthcare market segment

Awaira Score: Abridge scores 76/100 vs Nabla's 73/100

Which Should You Choose?

Use these signals to make the right call

Abridge logo

Choose Abridge if…

Top Pick
  • Higher Awaira Score — 76/100 vs 73/100
  • More established by valuation ($5.3B)
  • Stronger investor backing — raised $800M
  • United States-based for regional compliance or proximity
  • Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers
Nabla logo

Choose Nabla if…

  • France-based for regional compliance or proximity
  • Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows

Funding History

Abridge raised $800M across 4 rounds. Nabla raised $131M across 1 round.

Abridge

Series C

Jan 2023

$150M

Series B

Jan 2022

$30M

Series A

Jan 2021

$27M

Seed

Jan 2019

Nabla

Seed

Jan 2018

Investor Comparison

No shared investors detected between these two companies.

Unique to Abridge

Kleiner PerkinsLerer HippeauKhosla Ventures

Users Also Compare

FAQ — Abridge vs Nabla

Is Abridge bigger than Nabla?
By valuation, Abridge is the larger company at $5.3B versus $180M — a 29.4x difference. Size can also be measured by team: Abridge employs 120 people while Nabla has 80 employees.
Which company raised more funding — Abridge or Nabla?
Abridge has raised more in total funding at $800M, compared to Nabla's $131M — a gap of $669M. Combined, the two companies have completed 5 known funding rounds.
Which company has a higher Awaira Score?
Abridge leads with an Awaira Score of 76/100, while Nabla sits at 73/100. That 3-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.
Who founded Abridge vs Nabla?
Abridge was founded by Shiv Rao in 2018. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.
What does Abridge do vs Nabla?
Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology uses natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform applies natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.
Which company was founded first?
Both Abridge and Nabla launched in 2018. Same year, but even a few months' head start matters in AI — early movers lock in data, talent, and customer relationships fast.
Which company has more employees?
Abridge has about 120 employees; Nabla has about 80. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.
Are Abridge and Nabla competitors?
Yes — they're direct rivals. Both Abridge and Nabla compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.

Bottom Line

It's close. Both Abridge and Nabla are strong players, and picking a winner depends on what you're looking for. Check each profile for the full picture.

Who Should You Watch?

This one's genuinely too close to call. Both companies are competitive, and the winner will likely come down to execution over the next 12-18 months. Follow both profiles on Awaira to track funding rounds, team changes, and score updates.

Deep Dive